These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31102368)

  • 1. Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells.
    Sargazi S; Saravani R; Zavar Reza J; Zarei Jaliani H; Galavi H; Moudi M; Abtahi NA
    Iran Biomed J; 2019 Sep; 23(5):312-23. PubMed ID: 31102368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53.
    Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; Maretto M; Bassetti E; Caiazzo R; D'Orazi G; Cirone M
    Exp Cell Res; 2021 Nov; 408(2):112879. PubMed ID: 34653407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid.
    Sargazi S; Saravani R; Zavar Reza J; Jaliani HZ; Mirinejad S; Rezaei Z; Zarei S
    EXCLI J; 2019; 18():485-498. PubMed ID: 31423128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Guibbal F; Hopkins SL; Pacelli A; Isenegger PG; Mosley M; Torres JB; Dias GM; Mahaut D; Hueting R; Gouverneur V; Cornelissen B
    Mol Imaging Biol; 2020 Oct; 22(5):1226-1234. PubMed ID: 32342268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.
    Raineri A; Prodomini S; Fasoli S; Gotte G; Menegazzi M
    Biochem Pharmacol; 2019 Sep; 167():173-181. PubMed ID: 31185226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
    Camero S; Ceccarelli S; De Felice F; Marampon F; Mannarino O; Camicia L; Vescarelli E; Pontecorvi P; Pizer B; Shukla R; Schiavetti A; Mollace MG; Pizzuti A; Tombolini V; Marchese C; Megiorni F; Dominici C
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):137-152. PubMed ID: 30357520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
    Oplustil O'Connor L; Rulten SL; Cranston AN; Odedra R; Brown H; Jaspers JE; Jones L; Knights C; Evers B; Ting A; Bradbury RH; Pajic M; Rottenberg S; Jonkers J; Rudge D; Martin NM; Caldecott KW; Lau A; O'Connor MJ
    Cancer Res; 2016 Oct; 76(20):6084-6094. PubMed ID: 27550455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP1-siRNA suppresses human prostate cancer cell growth and progression.
    Lai Y; Kong Z; Zeng T; Xu S; Duan X; Li S; Cai C; Zhao Z; Wu W
    Oncol Rep; 2018 Apr; 39(4):1901-1909. PubMed ID: 29393407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
    Majuelos-Melguizo J; Rodríguez MI; López-Jiménez L; Rodríguez-Vargas JM; Martí Martín-Consuegra JM; Serrano-Sáenz S; Gavard J; de Almodóvar JM; Oliver FJ
    Oncotarget; 2015 Mar; 6(7):4790-803. PubMed ID: 25576921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of an AZD2461 [
    Reilly SW; Puentes LN; Schmitz A; Hsieh CJ; Weng CC; Hou C; Li S; Kuo YM; Padakanti P; Lee H; Riad AA; Makvandi M; Mach RH
    Bioorg Chem; 2019 Mar; 83():242-249. PubMed ID: 30390553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
    Chao OS; Goodman OB
    Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
    Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
    Wilkerson PM; Dedes KJ; Samartzis EP; Dedes I; Lambros MB; Natrajan R; Gauthier A; Piscuoglio S; Töpfer C; Vukovic V; Daley F; Weigelt B; Reis-Filho JS
    Oncotarget; 2017 Jan; 8(4):6057-6066. PubMed ID: 28002809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
    de Gooijer MC; Buil LCM; Çitirikkaya CH; Hermans J; Beijnen JH; van Tellingen O
    Mol Pharm; 2018 Nov; 15(11):5236-5243. PubMed ID: 30252484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.